Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja JA Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip YFL de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. Schellens, Christoph C. Zielinski, Suman Redhu, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Institutions: The University of Texas MD Anderson Cancer Center, National Institutes of Health, University of California, Los Angeles, Institut Gustave Roussy, University of Copenhagen, University Medical Center Hamburg-Eppendorf, Dana-Farber Cancer Institute, Heidelberg University, Erasmus MC, Erasmus MC Cancer Institute, Lyon 1 Université, Centre Léon Bérard, Institut Bergonié, New York Medical College, Utrecht University, University Medical Center Utrecht, Centre Hospitalier Universitaire de Nantes, Vall d'Hebron Institute of Oncology, The Netherlands Cancer Institute, Medical University of Vienna, Novartis (United States), Seoul National University Hospital
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4365513720